What is the current Digital Therapeutics for Nervous System Diseases market size?

The Digital Therapeutics for Nervous System Diseases market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Digital Therapeutics for Nervous System Diseases market?

Key drivers include rising prevalence of nervous system diseases and growing adoption of digital technologies.

What are the major challenges facing the market?

Challenges include high development costs and regulatory hurdles, impacting market growth.

Which regions are leading the Digital Therapeutics for Nervous System Diseases market?

North America and Europe are leading regions, driven by strong healthcare infrastructure.

Who are the top companies in the Digital Therapeutics for Nervous System Diseases market?

Top companies include major pharmaceutical and technology firms, such as Pfizer and Apple.

What future opportunities exist in the market?

Future opportunities include increasing use of AI and machine learning, and expanding into emerging markets.

How is technology impacting the Digital Therapeutics for Nervous System Diseases market?

Technology is enabling personalized treatment and improving patient outcomes, driving market growth.

What is the current regulatory landscape for the market?

The regulatory landscape is evolving, with increased focus on safety and efficacy, and clear guidelines emerging.

What is the future outlook for the Digital Therapeutics for Nervous System Diseases market?

The future outlook is positive, with increasing adoption and growing demand driving market expansion.

Global Digital Therapeutics for Nervous System Diseases Market Value Is Forecast To Reach By 2034 With CAGR

Digital Therapeutics for Nervous System Diseases by Application (Epilepsy, Parkinson's Disease, Alzheimer's Disease, Other), by Types (Prevention, Management, Treatment), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Digital Therapeutics for Nervous System Diseases Market Size | CAGR 15.2 Forecast 2033

Global Digital Therapeutics for Nervous System Diseases Market Value Is Forecast To Reach By 2034 With CAGR

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Digital Therapeutics for Nervous System Diseases Market Overview

The Digital Therapeutics for Nervous System Diseases market refers to the industry focused on developing and deploying digital solutions to treat and manage nervous system diseases. As the growth outlook for this market continues to evolve, the Digital Therapeutics for Nervous System Diseases market size is expected to reach approximately $1.4 billion by 2026. The market forecast indicates a promising expansion, driven by increasing adoption of digital health technologies and rising prevalence of nervous system diseases. The industry expansion is anticipated to be fueled by a compound annual growth rate (CAGR) of around 20%, with key drivers including advancements in technology shifts, changing regulations, and shifting consumer behavior.

Loading chart…

The North American region is currently the largest market for Digital Therapeutics for Nervous System Diseases, while the Asia-Pacific region is expected to be the fastest-growing market during the forecast period. Key forces shaping the industry include competitive intensity, supply-chain dynamics, and regulatory frameworks. As the market continues to evolve, it is essential for stakeholders to stay informed about the latest trends, opportunities, and challenges in the Digital Therapeutics for Nervous System Diseases market.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	38.29 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Zoecare; 66nao; MedRhythms; Curelator; Sanofi; GYENNO SCIENCE; Cognito Therapeutics; Nanjing Vishee Medical Technology Co.,Ltd.; Glecan; Xinkangyx; WonderLab; BestCovered,Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Digital Therapeutics for Nervous System Diseases market is poised for significant growth, driven by increasing demand for non-invasive and cost-effective treatments. The market dynamics are shaped by various factors, including technological advancements, regulatory frameworks, and shifting consumer preferences.

Growth Drivers2 items

Advances in digital therapeutics are enabling the development of personalized treatments for nervous system diseases, improving patient outcomes and driving market growth

The growing prevalence of nervous system diseases, such as Alzheimer's and Parkinson's, is fueling demand for innovative treatments, contributing to the Digital Therapeutics for Nervous System Diseases market size

Restraints2 items

Stringent regulatory requirements and the need for rigorous clinical trials are limiting the pace of innovation in the Digital Therapeutics for Nervous System Diseases market

High development costs and concerns about data privacy and security are hindering the adoption of digital therapeutics, impacting the growth forecast

Opportunities2 items

The increasing adoption of digital health technologies is creating new opportunities for digital therapeutics to address unmet medical needs in nervous system diseases

Collaborations between technology companies, pharmaceutical firms, and healthcare providers are driving innovation and growth in the Digital Therapeutics for Nervous System Diseases market

Challenges2 items

The lack of standardization in digital therapeutics is creating challenges for regulatory bodies, healthcare providers, and patients, affecting the overall Digital Therapeutics for Nervous System Diseases market size

The need for significant investment in infrastructure and training is limiting the adoption of digital therapeutics in underserved regions, impacting the growth forecast

Market Segmentation

Loading chart…

The Digital Therapeutics for Nervous System Diseases segmentation can be categorized based on application. This includes anxiety disorders, depression, insomnia, and other neurological disorders. Each application contributes to the overall market size, with anxiety disorders and depression being the largest segments. The application segment is crucial in understanding the Digital Therapeutics for Nervous System Diseases market as it highlights the specific areas where digital therapeutics are being utilized to treat nervous system diseases.

The types of digital therapeutics for nervous system diseases can be further segmented into prescription-based and non-prescription-based digital therapeutics. Prescription-based digital therapeutics require a doctor's prescription and are used to treat specific conditions, whereas non-prescription-based digital therapeutics are available over-the-counter and can be used by individuals without a doctor's prescription. Understanding the types of digital therapeutics is essential in market taxonomy as it helps to identify the different products and services being offered in the market.

Digital Therapeutics for Nervous System Diseases Segmentation Breakdown9 items

Application

Epilepsy

Parkinson's Disease

Alzheimer's Disease

Other

Types

Prevention

Management

Treatment

Regional Insights

Loading chart…

The Digital Therapeutics for Nervous System Diseases market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be the Asia Pacific, driven by increasing adoption of digital therapeutics, favorable policies, and significant investments in the healthcare sector.

Key drivers for each region include: for North America, a mature ecosystem, high infrastructure development, and a large patient population; for Europe, a strong regulatory framework, rising demographics of the elderly population, and growing investments in digital health; for Asia Pacific, increasing adoption of digital technologies, large patient population, and rising investments in healthcare infrastructure; for Latin America, growing demand for digital therapeutics, improving infrastructure, and increasing policies supporting digital health; and for Middle East & Africa, rising demand for digital therapeutics, growing investments in healthcare, and increasing adoption of digital technologies.

The regional forecast indicates a significant growth in the Digital Therapeutics for Nervous System Diseases market, with the Asia Pacific region expected to drive the market growth due to its large and growing patient population, increasing adoption of digital therapeutics, and rising investments in the healthcare sector. As the market continues to evolve, it is essential to monitor the regional forecast and market trends to capitalize on the growing opportunities in the Digital Therapeutics for Nervous System Diseases market.

Competitive Landscape

The Digital Therapeutics for Nervous System Diseases market exhibits a moderately consolidated structure, driven by a mix of global players and local companies. Key competitive levers include pricing, product innovation, and regulatory approvals, which are crucial for companies to navigate the Digital Therapeutics for Nervous System Diseases competitive landscape. Global players focus on advanced product development and strategic partnerships, while local companies concentrate on regional expansion and customization to cater to specific market needs.

Companies employ various strategies to differentiate themselves, including technology advancements, service model innovation, and channel strength. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies must prioritize strategic focuses such as regional expansion, innovation pipeline, and local manufacturing. The following companies illustrate these strategies:

Zoecare: regional expansion

66nao: innovation pipeline

MedRhythms: premium pricing

Curelator: local manufacturing

Sanofi: vertical integration

GYENNO SCIENCE: OEM tie-ups

Key Digital Therapeutics for Nervous System Diseases Companies12 items

Zoecare

66nao

MedRhythms

Curelator

Sanofi

GYENNO SCIENCE

Cognito Therapeutics

Nanjing Vishee Medical Technology Co.,Ltd.

Glecan

Xinkangyx

WonderLab

BestCovered,Ltd.

Market Ecosystem

The Digital Therapeutics for Nervous System Diseases ecosystem encompasses a complex network of stakeholders, spanning upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three main categories: upstream, midstream, and downstream. Upstream participants provide the foundational technologies and components, while midstream players integrate and refine these elements. Downstream channels and end users ultimately receive and utilize the digital therapeutics solutions, creating and capturing value through their adoption and usage.

Technology providers — develop core digital therapeutics technologies

System integrators — integrate digital therapeutics solutions

Distributors — manage distribution channels for digital therapeutics

Service providers — offer support and maintenance services

End users — utilize digital therapeutics solutions for treatment

Regulators — establish standards and approvals for digital therapeutics

Data/analytics providers — supply data analytics for digital therapeutics

Within the Digital Therapeutics for Nervous System Diseases ecosystem, control points and dependency risks significantly influence the flow of value. Regulators and standards bodies exert control over adoption through approvals and compliance requirements. Meanwhile, technology providers and system integrators face dependency risks related to input constraints, such as access to high-quality data and expertise in nervous system diseases. Switching costs and partnerships between ecosystem participants can also impact the ecosystem's overall efficiency and innovation. Furthermore, the ecosystem's dynamics can differ by region due to variations in regulatory frameworks, healthcare systems, and patient needs, underscoring the importance of a nuanced value chain analysis.

Recent Industry Insights

The Digital Therapeutics for Nervous System Diseases industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between key players have focused on integrating digital therapeutics into existing treatment protocols, enhancing patient outcomes. Notable mergers and acquisitions have also taken place, aiming to consolidate resources and expertise in the field.

Furthermore, there have been several product launches and technology updates, showcasing advancements in areas such as personalized medicine and artificial intelligence. Regulatory bodies have introduced guidelines to support the adoption of digital therapeutics, and there is a noticeable shift in consumer trends towards preferring digital health solutions. Additionally, the industry has seen substantial funding rounds and expansions, underscoring the growing interest and investment in digital therapeutics for nervous system diseases.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Digital Therapeutics for Nervous System Diseases market outlook. The market exhibits high attractiveness due to the growing prevalence of nervous system diseases and the increasing adoption of digital therapeutics. The competitive intensity is moderate, with key players investing heavily in research and development to stay ahead. The long-term outlook is promising, driven by advancements in technology and the expanding scope of digital therapeutics.

The innovation landscape is rapidly evolving, with emerging technologies such as artificial intelligence and virtual reality transforming the market. The demand-supply balance is expected to remain stable, with increasing demand for digital therapeutics met by a growing number of market entrants. However, key risk factors such as regulatory uncertainty and data security concerns may impact market growth. Overall, the market presents opportunities for investors and stakeholders to capitalize on the growing demand for digital therapeutics.

11 items

1. Executive Summary

2. Digital Therapeutics for Nervous System Diseases Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Digital Therapeutics for Nervous System Diseases Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Digital Therapeutics for Nervous System Diseases Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Epilepsy

6.1.2. Parkinson's Disease

6.1.3. Alzheimer's Disease

6.1.4. Other

6.2. Global Digital Therapeutics for Nervous System Diseases Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Prevention

6.2.2. Management

6.2.3. Treatment

6.3. Global Digital Therapeutics for Nervous System Diseases Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Digital Therapeutics for Nervous System Diseases Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Digital Therapeutics for Nervous System Diseases Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Digital Therapeutics for Nervous System Diseases Market Competition by Key Manufacturers

8.1. Global Digital Therapeutics for Nervous System Diseases Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Digital Therapeutics for Nervous System Diseases: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Zoecare

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. 66nao

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. MedRhythms

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Curelator

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Sanofi

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. GYENNO SCIENCE

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Cognito Therapeutics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Nanjing Vishee Medical Technology Co.,Ltd.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Glecan

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Xinkangyx

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. WonderLab

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. BestCovered,Ltd.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Digital Therapeutics for Nervous System Diseases Market

Figure 4: Global Digital Therapeutics for Nervous System Diseases Market: Drivers

Figure 5: Global Digital Therapeutics for Nervous System Diseases Market: Challenges

Figure 6: Global Digital Therapeutics for Nervous System Diseases Market: Trends

Figure 7: Global Digital Therapeutics for Nervous System Diseases Market: Opportunity

Figure 8: Global Digital Therapeutics for Nervous System Diseases Market: Restraint

Figure 9: Global Digital Therapeutics for Nervous System Diseases Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Digital Therapeutics for Nervous System Diseases Market Value (USD Million) By Region

Figure 15: Global Digital Therapeutics for Nervous System Diseases Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Digital Therapeutics for Nervous System Diseases Market Value (USD Million) By Region

Figure 23: Global Digital Therapeutics for Nervous System Diseases Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Digital Therapeutics for Nervous System Diseases Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Digital Therapeutics for Nervous System Diseases Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Digital Therapeutics for Nervous System Diseases Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Digital Therapeutics for Nervous System Diseases Market Value (USD Million) By Region

Table 10: Global Digital Therapeutics for Nervous System Diseases Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Digital Therapeutics for Nervous System Diseases Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Digital Therapeutics for Nervous System Diseases Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Digital Therapeutics for Nervous System Diseases Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Zoecare Basic Information And Sales Area

Table 31: Zoecare. Products Portfolio

Table 32: 66nao Basic Information And Sales Area

Table 33: 66nao. Products Portfolio

Table 34: MedRhythms Basic Information And Sales Area

Table 35: MedRhythms. Products Portfolio

Table 36: Curelator Basic Information And Sales Area

Table 37: Curelator. Products Portfolio

Table 38: Sanofi Basic Information And Sales Area

Table 39: Sanofi. Products Portfolio

Table 40: GYENNO SCIENCE Basic Information And Sales Area

Table 41: GYENNO SCIENCE. Products Portfolio

Table 42: Cognito Therapeutics Basic Information And Sales Area

Table 43: Cognito Therapeutics. Products Portfolio

Table 44: Nanjing Vishee Medical Technology Co.,Ltd. Basic Information And Sales Area

Table 45: Nanjing Vishee Medical Technology Co.,Ltd.. Products Portfolio

Table 46: Glecan Basic Information And Sales Area

Table 47: Glecan. Products Portfolio

Table 48: Xinkangyx Basic Information And Sales Area

Table 49: Xinkangyx. Products Portfolio

Table 50: WonderLab Basic Information And Sales Area

Table 51: WonderLab. Products Portfolio

Table 52: BestCovered,Ltd. Basic Information And Sales Area

Table 53: BestCovered,Ltd.. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Digital Therapeutics for Nervous System Diseases Market Value (USD Million) By Region

Table 59: Global Digital Therapeutics for Nervous System Diseases Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Digital Therapeutics for Nervous System Diseases Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	38.29 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Zoecare; 66nao; MedRhythms; Curelator; Sanofi; GYENNO SCIENCE; Cognito Therapeutics; Nanjing Vishee Medical Technology Co.,Ltd.; Glecan; Xinkangyx; WonderLab; BestCovered,Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options